News for Providers
Top editor picks, summarized for you
8/26/2016

Mallinckrodt's Synacthen Depot, or tetracosactide, has received fast-track status from the FDA as a treatment for Duchenne muscular dystrophy. The drug, a long-acting depot formulation of a synthetic 24 amino acid melanocortin receptor agonist, is being assessed in an early-stage trial.

Full Story:
eMPR.com
More Summaries:
Mallinckrodt, FDA, Synacthen Depot
8/26/2016

A volunteer firefighter received a face transplant last August in an operation that reconstructive surgeon Eduardo Rodriguez said was the most extensive face transplant to date. The patient's hair, eyelids, ears, lips and most of his nose were burned off in a 2001 house fire, but since the transplant he is no longer afraid to be seen in public.

Full Story:
CNN, Time.com
More Summaries:
Eduardo Rodriguez
8/26/2016

Danish researchers found that type 2 diabetes patients had a significantly slower decline in estimated glomerular filtration rate and reduced albuminuria two years after receiving the SGLT2 inhibitor canagliflozin in either 100 mg or 300 mg daily, in addition to metformin and a renin-angiotensin system inhibitor, compared with those on the sulfonylurea glimepiride. The findings in the Journal of the American Society of Nephrology, based on 1,450 diabetes patients, suggested that little between-group differences in A1C levels were not mediated by blood glucose.

8/26/2016

Patients who had early exposure to diabetes had early diastolic strain rate, longitudinal systolic strain, and less favorable left ventricular mass and ejection fraction, compared with the normal glucose tolerance group, according to a study in JACC: Cardiovascular Imaging. Researchers used a cohort of 3,179 participants from the Coronary Artery Risk Development in Young Adults Year-25 examination, ages 43 to 55, and found that high insulin resistance was associated with worse relative wall thickness and longitudinal systolic strain and early diastolic strain rate, depending on the level of obesity.

8/26/2016

Mettle Studio's wearable Proximity Button is designed to help caregivers locate dementia patients if they wander. Patients attach the device to clothing and if they travel beyond a set distance an alarm is sent to their caregiver's smartphone.

Full Story:
Design Week (U.K.)
8/26/2016

A study published in The Lancet Neurology found that specialized stroke ambulances, which can identify the type of stroke and administer thrombolysis treatment in transit if necessary, reduce the risk of severe disabilities and improve the patient survival rate, compared with treatment received upon arrival at the hospital. The mobile stroke units are outfitted with a mini laboratory, CT scanner and thrombolysis treatment supplies.

More Summaries:
The Lancet Neurology
8/26/2016

Preterm infants who received music therapy had more stabilized breathing rates and were discharged from the NICU three days earlier than those who didn't have music therapy. The findings in Pediatrics, based on a review of 14 clinical trials involving nearly 1,000 premature babies, also showed lower stress levels among mothers who sang to their infants in the NICU.

Full Story:
HealthDay News
More Summaries:
NICU
8/26/2016

Children with food allergies may be at higher risk of asthma, researchers from Children’s Hospital of Philadelphia reported in BMC Pediatrics. The risk increased among children with more than one food allergy, researchers said.

Full Story:
HCPLive
More Summaries:
asthma, BMC Pediatrics
8/26/2016

The Tucson Unified School District in Arizona is making cakes and cookies with alternative ingredients, such as black beans and fruit, to reduce their sugar content. District dietitian Lindsay Aguilar said parents and schools want to find ways to limit sugar-laden snacks outside of regular meals.

8/26/2016

NIH scientists and researchers from the Johns Hopkins Bloomberg School of Public Health are working together to develop a vaccine candidate that will protect people not only from Zika but also from dengue. The human challenge portion of the trial, to begin in December, aims to test the efficacy of a vaccine candidate that needs to be strong enough to evoke a protective antibody response while also being weak enough not to be transmitted sexually or through blood from mosquito bites.

Full Story:
FoxNews.com